2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

4:30PM-6:00PM: Abstract Number: 955

Lower Limb Muscle Strength and Protection Against Functional Decline and Structural Worsening in Knee Osteoarthritis

3S105 ACR Abstract: Osteoarthritis–Clinical (952–957)

4:30PM-6:00PM: Abstract Number: 921

Multi-Omics Analysis Identifies a Gene Signature Associated with the Clinical Response to Anti-TNF Therapy in Rheumatoid Arthritis

3S103 ACR Abstract: Genetics, Genomics & Proteomics: Precision Medicine (916–921)

4:30PM-6:00PM: Abstract Number: 935

Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Lipocalin-2

3S109 ACR Abstract: SLE–Animal Models (934–939)

4:30PM-6:00PM: Abstract Number: 923

Neutrophils from Children with Systemic JIA Exhibit Persistent Proinflammatory Activation Despite Long-Standing Clinically Inactive Disease

3S106 ACR Abstract: Pediatric Rheumatology–Basic Science (922–927)

4:30PM-6:00PM: Abstract Number: 981

New Consensus on an Updated Core Domain Set for Clinical Trials in Juvenile Idiopathic Arthritis

3S115 ACR/ARHP Abstract: Pediatric Rheum (976–981)

4:30PM-6:00PM: Abstract Number: 977

Nurse Led Safe Switching from Original Reference Product Infliximab to Biosimalar in Patients with Juvenile Idiopathic Arthritis and Uveitis – a Single Centre Experience Including Baseline and Post Switch Infliximab Levels and Antibodies

3S115 ACR/ARHP Abstract: Pediatric Rheum (976–981)

4:30PM-6:00PM: Abstract Number: 969

Obstetric Outcomes in Women with Psoriatic Arthritis: Results from Nationwide Inpatient Sample Database 2003-2011

3S111 ACR Abstract: Spondyloarthritis Incl PsA–Clinical II: PsA Epidemiology (964–969)

4:30PM-6:00PM: Abstract Number: 945

Pain, Functional Limitations and Physical Activity Participation Trajectories in Patients with Symptomatic Knee and Hip Osteoarthritis: A Multi-Trajectory Analysis

3S102 ACR Abstract: Epidemiology & Pub Health I: Morbidity & Mortality (940–945)

4:30PM-6:00PM: Abstract Number: 931

Patients with Seropositive Rheumatoid Arthritis Who Do Not Mount a CRP Response When They Have Synovitis Are Immunologically Distinct and Are Poorly Served By Current Management Strategies

3S107 ACR Abstract: RA–Etiology & Pathogenesis I (928–933)

4:30PM-6:00PM: Abstract Number: 964

Psoriatic Arthritis Impact of Disease (PsAID12) Was Provisionally Endorsed at Omeract 2018 As Core Instrument to Measure Psoriatic Arthritis-Specific Health-Related Quality of Life in Randomized Controlled Trials and Longitudinal Observational Studies

3S111 ACR Abstract: Spondyloarthritis Incl PsA–Clinical II: PsA Epidemiology (964–969)

4:30PM-6:00PM: Abstract Number: 939

Rab4A Protects from Lupus Nephritis By Limiting Germinal Center Formation and Pro-Inflammatory Expression of GLUT1 and Integrin By Renal Epithelial Cells

3S109 ACR Abstract: SLE–Animal Models (934–939)

4:30PM-6:00PM: Abstract Number: 920

Rheumatoid Arthritis Patient-Specific Therapeutic Target Identification Using Integrative Epigenetic Profiling

3S103 ACR Abstract: Genetics, Genomics & Proteomics: Precision Medicine (916–921)

4:30PM-6:00PM: Abstract Number: 943

Risk of Prostate Cancer in US Veterans with Rheumatoid Arthritis

3S102 ACR Abstract: Epidemiology & Pub Health I: Morbidity & Mortality (940–945)

4:30PM-6:00PM: Abstract Number: 942

Risk of Serious Infections in Tocilizumab Versus TNF Inhibitor Initiators in Patients with RA: A Multi-Database Cohort Study

3S102 ACR Abstract: Epidemiology & Pub Health I: Morbidity & Mortality (940–945)

4:30PM-6:00PM: Abstract Number: 962

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis

3S108 ACR Abstract: RA–Treatments II: Safety (958–963)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].